Added to YB: 2026-08-13
Pitch date: 2026-08-10
RMD [neutral]
ResMed Inc.
+3.3%
current return
Author Info
Heavy Moat Investments is on a journey to find high-quality businesses with a long-term investment horizon of all sizes. Sign up for the newsletter.
Company Info
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
Market Cap
$31.7B
Pitch Price
$218.78
Price Target
N/A
Dividend
1.20%
EV/EBITDA
14.35
P/E
21.10
EV/Sales
5.50
Sector
Health Care Equipment and Supplies
Category
growth
Is ResMed a sleep well at night investment?
RMD (overview): Sleep apnea near-monopolist after Philips' 2021 CPAP foam recall exit. Undertreated market (<15-20% US, <5-10% global diagnosis), aging/higher-BMI tailwinds. Recurring revenue via consumables & software (insurance reimbursement moat). 12% rev CAGR, 19% FCF CAGR, 33% EBIT margin at 17.5x fwd earnings. Risks: GLP-1s (no proven correlation yet) & emerging drugs like Apnimed (56% fewer events, 22% full control vs placebo).
Read full article (3 min)